

**Alcidion Group Limited (ABN 77 143 142 410)**
**Appendix 4D**
**& Financial statements for the period ended 31 December 2025**
**Results for announcement to the market**
**Reporting Periods**

Current reporting period	Half-year ended 31 December 2025
Previous reporting period	Half-year ended 31 December 2024

**Key information**

	% Change	\$000
Total revenue from ordinary activities	Up 44% to	\$25,470
Profit from ordinary activities after tax attributable to members	NM <sup>1</sup>	\$1,330
Net profit for the period attributable to members	NM <sup>1</sup>	\$1,330

1) Not Meaningful: As the Group was in a loss position in the prior year, the % change movement relating to the improved performance (i.e. prior year loss moving to current year profit) displays as a negative % change for these results.

**Details relating to dividends**

No dividends were paid or proposed for the current or previous corresponding half-year period.

**Explanation of results**

First half revenue at \$25,470k is 44% higher than prior corresponding period (PCP), this increase is largely due to continued momentum from new sales such as the NCIC Mizaic and Leidos expansion contracts signed and announced in September 2025 and November 2025 respectively. It also includes the full six-month impact of the NCIC EPR contract and Hywel Dda Health Board recurring and services revenue (these contracts were signed in PY H2 and did not contribute to the PCP revenue).

Loss from ordinary activities after tax attributable to members increased from a loss of \$889k in the PCP to a \$1,330k profit in the current reporting period, this improvement is a result of the revenue increase discussed above and steady maintenance of operating costs.

Additional information supporting the Appendix 4D disclosure requirements can be found in the Directors' report and the consolidated financial statements for the half-year ended 31 December 2025 lodged with this document.

**Net tangible assets per security**

	31 December 2025	30 June 2025
Net tangible assets per security	\$0.001	(\$0.002)

This Appendix 4D is based on the attached half-year financial report which has been reviewed by the Group's auditors, William Buck. A copy of William Buck's review report is included in the attached half-year financial report.

For personal use only

For personal use only

# **Alcidion Group Limited**

**Financial report for the half year  
ended 31 December 2025**



## CONTENTS

Directors' Report .....	1
Auditor's Independence Declaration .....	5
Consolidated Statement of Profit or Loss and Other Comprehensive Income .....	6
Consolidated Statement of Financial Position .....	7
Consolidated Statement of Changes in Equity .....	8
Consolidated Statement of Cash Flows .....	9
Notes to the Financial Statements .....	10
Directors' Declaration .....	16
Independent Auditor's Review Report .....	17
Corporate Directory .....	19

For personal use only

## Directors' Report

The directors submit herewith the financial report of Alcidion Group Limited and its subsidiaries ("Alcidion", "the Group" or, the "Company") for the half-year ended 31 December 2025. In order to comply with the provisions of the *Corporations Act 2001*, the directors report as follows:

### Directors

The following persons were directors of Alcidion Group Limited during the whole of the financial half-year and up to the date of this report, unless otherwise stated:

Ms Rebecca Wilson	Mr Daniel Sharp	Prof. Andrew Way AM
Ms Kate Quirke	Mr William Smart	

### Principal activities

The principal activities of Alcidion include the development and licensing of its own healthcare software products (Miya Precision and its associated modules, including Miya Observations, Flow, Task Management and Patient Administration System (PAS)), the reselling of selected healthcare software products from its strategic partners and the delivery of product implementation, product support and maintenance, to healthcare customers in Australia, New Zealand and the United Kingdom.

### Review of operations

#### Profit and loss

##### Summary of profit and loss:

	31 Dec 2025	30 Dec 2024	Change	Change
	\$000	\$000	\$000	%
Revenue	25,470	17,638	7,832	+44%
Margin	21,016	15,366	5,650	+37%
Margin %	83%	87%		
Underlying EBITDA	4,192	541	3,651	+675%
Profit/(loss) after tax	1,330	(889)	2,219	NM <sup>1</sup>

1) Not Meaningful: As the Group was in a loss position in the prior year, the % change movement relating to the improved performance (i.e. prior year loss moving to current year profit) displays as a negative % change for these results

Revenue for the Group for the first half of FY26 is \$25.5M which has increased \$7.8M (44%) on the PCP.

In Australia, the inclusion of a full 6 months of revenue from prior year sales such as Peninsula Health and North Adelaide Local Health Network (NALHN) as well as the contribution from the Leidos contract expansion announced in November 2025 has seen ANZ revenue increase \$2.1M (+21%) versus the prior corresponding period (PCP).

In the UK, the inclusion of 6 months revenue from North Cumbria Integrated Care NHS Foundation Trust (NCIC) and Hywel Dda (both signed in February 2025) as well as the inclusion of a \$1.0M Capital licence from the Contract expansion to deliver MediViewer from our partner Mizaic to NCIC announced in September 2025 has seen UK revenue increase \$5.8M (+76%) versus the PCP.

Together, this has resulted in an overall increase in Group revenue of \$7.8M (+44%), which has resulted in a \$5.7M increase in gross profit to \$21.0M. The percentage margin saw a decrease from 87% to 83%, driven by direct costs, which in this case saw an unusually larger component of third-party software costs associated with the Leidos and Mizaic deployments.

The business continued its focus on tight cost control, seeing staff costs increase 4.8% versus PCP and non-staff operating expenditure increase 14% versus PCP, subsequently delivering a material increase in underlying EBTIDA of \$3.7M to deliver a record first half underlying EBITDA of \$4.2M.

**Reconciliation of Profit/(loss) after tax to non-IFRS EBITDA & underlying EBITDA:**

<b>Half-year ended:</b>	<b>31 Dec 2025</b>	<b>31 Dec 2024</b>
	<b>\$000</b>	<b>\$000</b>
<b>Profit/(loss) after tax attributable to the owners of the company</b>	<b>1,330</b>	<b>(889)</b>
<i>Add:</i>		
Depreciation & amortisation expense	2,368	1,453
Finance costs	32	40
<i>Less:</i>		
Income tax (expense) / benefit	(231)	218
Interest income	89	57
<b>EBITDA profit</b>	<b>3,872</b>	<b>329</b>
<i>Add back:</i>		
Restructure costs	220	116
Non-cash cost of performance rights	100	96
<b>Underlying EBITDA profit</b>	<b>4,192</b>	<b>541</b>

## Financial position

**Summary of financial position:**

	<b>31 Dec 2025</b>	<b>30 June 2025</b>
	<b>\$000</b>	<b>\$000</b>
Cash and cash equivalents	14,195	17,697
Net current assets	6,192	2,825
Net assets/equity	89,638	87,801
Net tangible assets	1,172	(2,551)

## Equity

**Summary of share capital:**

	<b>31 Dec 2025</b>	<b>30 June 2025</b>
Issued capital (\$000)	115,515	115,515
No. of issued shares	1,342,952,696	1,342,952,696
No. performance rights	31,032,466	26,475,983
Share price (\$)	0.105	0.100
Market capitalisation (\$M)	141.0	134.3

## Significant contract wins and renewals

During the first half of the financial year, Alcidion contracted new sales and renewals with a total contract value (TCV) of \$23.6M.

Significant new sales signed in the period include:

### **North Cumbria Integrated Care NHS Foundation Trust (NCIC)**

In September 2025 Alcidion announced that it had signed a contract expansion with NCIC to deliver MediViewer as an expansion to the Miya Precision Electronic Patient Record (EPR) solution, providing seamless access to scanned and historical documents in clinical workflows.

The TCV of this agreement is approximately \$6.8M over 9.4 years, aligning with the existing 10-year contract.

### **Leidos Australia**

In November 2025 Alcidion announced the signing of a contract expansion with Leidos Australia to further expand the use of Miya Precision to enable Leidos to deliver on commitments to the Commonwealth of Australia. The contract expansion is for additional software modules from Miya Precision to enable Leidos to deliver further solution components to the Commonwealth of Australia

The total contract value for the expansion is \$12.3M for the period until June 2028, adding a further \$2.5M to Alcidion's ARR.

## Likely developments and expected results

Subsequent to the period end Alcidion announced that following a competitive tender process it had been selected as the preferred EPR supplier by University Hospitals Sussex NHS Foundation Trust (UHSussex). Total Contract Value (TCV) is under negotiation but is anticipated to be in excess of \$35.0M depending on the number of modules included, over a minimum 7-year period. Upon finalising the contract, Alcidion is targeting deployment commencement in Q4 FY26.

As at 31 December 2025, the total FY26 sold and renewal revenue was \$43.1M, this does not include any revenue contribution from the University Hospitals Sussex EPR contract negotiation nor other potential new contract wins which may occur over the course of the second half of the financial year.

Building on our strong first half performance, full year FY26 EBITDA and cash flow are expected to be at least in line with FY25, with the potential upside dependent on the successful completion of the University Hospitals Sussex contract and continued conversion of new revenue opportunities.

## Significant changes in state of affairs

### **Shares on issue and performance rights:**

On 11 August 2025 449,603 performance rights were forfeited.

On 31 October 2025 5,424,777 performance rights were forfeited.

On 26 November 2025 the Company issued 10,430,863 performance rights to employees in accordance with the Alcidion Group Limited Equity Incentive Plan.

Other than the above, no significant changes in the state of affairs of the Group occurred during the interim period.

## Significant events after the balance date

Subsequent to the period end Alcidion announced that it has been selected as the preferred EPR supplier by University Hospitals Sussex NHS Foundation Trust (UHSussex) for its new Electronic Patient Record (EPR) system. Details of this expected contract can be found above in Likely developments and expected results.

Other than the events detailed above, there were no significant events after 31 December 2025.

## Dividends

No dividends were paid or declared during the half year and no recommendation for payment of dividends has been made. (Prior year: \$Nil)

## Rounding


The Company is a company of the kind referred to in *ASIC Corporations (Rounding in Financials/Directors' Reports) Instruments 2016/191*, dated 24 March 2016, and in accordance with that Corporations Instrument amounts in this directors' report and financial report are rounded off to the nearest thousand dollars, unless otherwise indicated.

## Auditors Independence Declaration

A copy of the auditor's independence declaration as required under s.307C of the Corporations Act 2001 is set out on page 5.

Signed in accordance with a resolution of directors made pursuant to s.306(3) of the Corporations Act 2001.

On behalf of the Directors



**Rebecca Wilson**  
Non-Executive Chair  
Melbourne, 26 February 2026

## Auditor's Independence Declaration



### Lead Auditor's Independence Declaration under Section 307c of the Corporations Act 2001

#### To the Directors of Alcidion Group Limited

As lead auditor for the review of Alcidion Group Limited for the half-year ended 31 December 2025, I declare that, to the best of my knowledge and belief, there have been:

- no contraventions of the auditor independence requirements as set out in the *Corporations Act 2001* in relation to the review; and
- no contraventions of any applicable code of professional conduct in relation to the review.

This declaration is in respect of Alcidion Group Limited and the entities it controlled during the period.



**William Buck (SA)**  
ABN: 38 280 203 274



**G.W. Martinella**  
Partner

Dated this 26<sup>th</sup> day of February, 2026.

For personal use only

## Statement of profit or loss and other comprehensive income

CONSOLIDATED	Note	31 Dec 2025 \$000	31 Dec 2024 \$000
Revenue	3	25,470	17,638
Direct costs		(4,454)	(2,272)
<b>Gross Profit</b>		<b>21,016</b>	<b>15,366</b>
Interest income		89	57
Employee benefits expense		(13,538)	(12,921)
Professional fees		(745)	(628)
Marketing expenses		(348)	(299)
Other expenses		(2,036)	(1,822)
Foreign exchange (loss)/gain		(477)	633
Depreciation and amortisation expense	4	(2,368)	(1,453)
Finance costs		(32)	(40)
<b>Profit/(loss) before income tax expense</b>		<b>1,561</b>	<b>(1,107)</b>
Income tax (expense) / benefit		(231)	218
<b>Profit/(loss) after tax attributable to the owners of the Company</b>		<b>1,330</b>	<b>(889)</b>
<b>Other comprehensive income/(loss) net of tax</b> <i>Items that may be reclassified subsequently to profit or loss:</i>			
Exchange differences on translation of foreign operations		407	(809)
<b>Total comprehensive profit/(loss) for the half year attributable to the owners of the Company</b>		<b>1,737</b>	<b>(1,698)</b>
<b>Earnings/(loss) Per Share</b>			
Basic and diluted earnings/(loss) per share (cents)	9	0.10	(0.07)

The notes following the financial statements form part of the financial report.

## Statement of financial position

CONSOLIDATED		31 Dec 2025	30 June 2025
	Note	\$000	\$000
<b>Current assets</b>			
Cash and cash equivalents		14,195	17,697
Trade and other receivables	5	12,417	3,680
Other assets		1,908	2,310
<b>Total current assets</b>		<b>28,520</b>	<b>23,687</b>
<b>Non-current assets</b>			
Plant and equipment		193	250
Intangible assets	6	88,466	90,352
Right of use assets		906	1,337
<b>Total non-current assets</b>		<b>89,565</b>	<b>91,939</b>
<b>Total assets</b>		<b>118,085</b>	<b>115,626</b>
<b>Liabilities</b>			
<b>Current liabilities</b>			
Trade and other payables		5,892	2,275
Employee provisions		3,066	2,927
Lease liabilities		680	711
Income tax payable		709	(89)
Unearned revenue		11,981	15,038
<b>Total current liabilities</b>		<b>22,328</b>	<b>20,862</b>
<b>Non-current liabilities</b>			
Employee provisions		180	182
Other provisions		462	470
Deferred tax liabilities		5,159	5,617
Lease liabilities		318	694
<b>Total non-current liabilities</b>		<b>6,119</b>	<b>6,963</b>
<b>Total liabilities</b>		<b>28,447</b>	<b>27,825</b>
<b>Net assets</b>		<b>89,638</b>	<b>87,801</b>
<b>Equity</b>			
Issued capital	7	115,515	115,515
Share based payment reserves		1,328	1,228
Foreign currency translation reserve		(169)	(576)
Accumulated losses		(27,036)	(28,366)
<b>Total equity</b>		<b>89,638</b>	<b>87,801</b>

The notes following the financial statements form part of the financial report.

## Statement of changes in equity

CONSOLIDATED	Issued capital	Share based payment reserves	Foreign currency translation reserve	Accumulated losses	Total equity
	\$000	\$000	\$000	\$000	\$000
<b>Balance as at 1 July 2024</b>	<b>115,515</b>	<b>1,094</b>	<b>351</b>	<b>(30,020)</b>	<b>86,940</b>
Loss for the period	-	-	-	(889)	(889)
Other comprehensive income net of tax	-	-	(809)	-	(809)
<b>Total comprehensive income</b>	<b>-</b>	<b>-</b>	<b>(809)</b>	<b>(889)</b>	<b>(1,698)</b>
<i>Transactions with owners in their capacity as owners:</i>					
Share capital issued	-	-	-	-	-
Share-based payment expense	-	96	-	-	96
<b>Balance at 31 Dec 2024</b>	<b>115,515</b>	<b>1,190</b>	<b>(458)</b>	<b>(30,909)</b>	<b>85,338</b>
<b>Balance as at 1 July 2025</b>	<b>115,515</b>	<b>1,228</b>	<b>(576)</b>	<b>(28,366)</b>	<b>87,801</b>
Gain for the period	-	-	-	1,330	1,330
Other comprehensive income net of tax	-	-	407	-	407
<b>Total comprehensive income</b>	<b>-</b>	<b>-</b>	<b>407</b>	<b>1,330</b>	<b>1,737</b>
<i>Transactions with owners in their capacity as owners:</i>					
Share capital issued	-	-	-	-	-
Share-based payment expense	-	100	-	-	100
<b>Balance at 31 Dec 2025</b>	<b>115,515</b>	<b>1,328</b>	<b>(169)</b>	<b>(27,036)</b>	<b>89,638</b>

The notes following the financial statements form part of the financial report.

## Statement of cash flows

<b>CONSOLIDATED</b>	<b>Note</b>	<b>31 Dec 2025 \$000</b>	<b>31 Dec 2024 \$000</b>
<b>Cash flows from operating activities</b>			
Receipts from customers		16,957	15,342
Payments to suppliers and employees		(19,577)	(19,481)
Interest received		89	57
Finance costs		(32)	(40)
<b>Net cash (outflow) from operating activities</b>		<b>(2,563)</b>	<b>(4,122)</b>
<b>Cash flows from investing activities</b>			
Payments for plant and equipment		(32)	(10)
<b>Net cash (used) for investing activities</b>		<b>(32)</b>	<b>(10)</b>
<b>Cash flows from financing activities</b>			
Proceeds from issues of equity securities		-	-
Transaction costs related to issues of equity securities		-	-
Repayment of principal on lease liabilities		(371)	(346)
<b>Net cash (outflows) from financing activities</b>		<b>(371)</b>	<b>(346)</b>
Net (decrease) in cash and cash equivalents		(2,966)	(4,478)
Effects of exchange rate changes on cash and cash equivalents		(536)	361
Cash and cash equivalents at the beginning of the period		17,697	11,798
<b>Cash and cash equivalents at the end of the period</b>		<b>14,195</b>	<b>7,681</b>

The notes following the financial statements form part of the financial report.

## Notes to the financial statements

### 1. General information

Alcidion Group Limited (“Alcidion” or the “Group” or the “Company”) is a limited company incorporated in Australia. The core of Alcidion’s business model is to create intellectual property in the form of Clinical Information System software developed to improve the quality of care for all patients and improve the productivity of clinicians and care teams.

The Company’s software is bundled with other technologies and services to create complete clinical and business solutions for healthcare providers. Alcidion builds, sells, delivers, hosts and supports solutions for health care provider organisations in Australia, New Zealand and the United Kingdom.

### 2. Material accounting policy information

These consolidated financial statements are general purpose interim financial statements which have been prepared in accordance with the Corporations Act 2001, and Australian Accounting Standard AASB 134: Interim Financial Reporting. Compliance with AASB 134 ensures compliance with International Financial Reporting Standard IAS 34 ‘Interim Financial Reporting’

This interim financial report is intended to provide users with an update on the latest annual financial statements of the Group. As such, it does not contain information that represents relatively immaterial changes occurring during the half-year within the Group. It is therefore recommended that this financial report be read in conjunction with the annual financial statements of the Group for the year ended 30 June 2025, together with any public announcements made during the half year.

The half-year financial statements were authorised for issue by the directors on 26 February 2026.

#### 2.1 Basis of preparation

The financial statements comprise the consolidated financial statements of the Group which comprises the Company and its legal subsidiaries. For the purposes of preparing the consolidated financial statements, the Group is a for-profit entity. Except for the changes disclosed at Note 2.2 below, the same accounting policies and methods of computation have been followed in this interim financial report as were applied in the most recent financial statements.

The condensed interim financial consolidated financial statements of the Group are for the six months ended 31 December 2025 and are presented in Australian Dollars (\$), which is the functional currency of the Parent Company.

#### 2.2 New or amended accounting standard and interpretations adopted

The Group has adopted all new or amended Accounting Standards and Interpretations issued by the Australian Accounting Standards Board (‘AASB’) that are mandatory for the current reporting period. There has been no impact from this adoption.

Any new or amended Accounting Standards or Interpretations that are not yet mandatory have not been adopted early.

### 3. Revenue

	<b>31 Dec 2025</b>	<b>31 Dec 2024</b>
	<b>\$000</b>	<b>\$000</b>
Annual Recurring revenue	19,279	13,689
Capital licence revenue	993	-
Non-recurring revenue	5,198	3,949
<b>Total revenue</b>	<b>25,470</b>	<b>17,638</b>

### 4. Depreciation and amortisation

	<b>31 Dec 2025</b>	<b>31 Dec 2024</b>
	<b>\$000</b>	<b>\$000</b>
Depreciation of plant and equipment	86	145
Depreciation of right of use assets	396	410
Amortisation of intangible assets	1,886	898
<b>Total Depreciation and amortisation</b>	<b>2,368</b>	<b>1,453</b>

### 5. Trade and other receivables

	<b>31 Dec 2025</b>	<b>30 June 2025</b>
	<b>\$000</b>	<b>\$000</b>
Trade receivables	10,724	3,680
Accrued income	1,693	-
	<b>12,417</b>	<b>3,680</b>

**6. Intangible assets**

	<b>Goodwill \$000</b>	<b>Customer contracts \$000</b>	<b>Acquired Software \$000</b>	<b>Patents &amp; Trademarks \$000</b>	<b>Total \$000</b>
<b>Cost</b>					
<b>At 1 July 2024</b>	<b>67,763</b>	<b>15,595</b>	<b>16,399</b>	<b>341</b>	<b>100,098</b>
Additions	-	-	-	-	-
<b>At 30 June 2025</b>	<b>67,763</b>	<b>15,595</b>	<b>16,399</b>	<b>341</b>	<b>100,098</b>
<b>At 1 July 2025</b>					
<b>At 1 July 2025</b>	<b>67,763</b>	<b>15,595</b>	<b>16,399</b>	<b>341</b>	<b>100,098</b>
Additions	-	-	-	-	-
<b>At 31 December 2025</b>	<b>67,763</b>	<b>15,595</b>	<b>16,399</b>	<b>341</b>	<b>100,098</b>
<b>Accumulated amortisation</b>					
<b>At 1 July 2024</b>	-	<b>2,389</b>	<b>3,601</b>	<b>157</b>	<b>6,147</b>
Amortisation expense	-	2,174	1,367	58	3,599
<b>At 30 June 2025</b>	-	<b>4,563</b>	<b>4,968</b>	<b>215</b>	<b>9,746</b>
<b>At 1 July 2025</b>					
<b>At 1 July 2025</b>	-	<b>4,563</b>	<b>4,968</b>	<b>215</b>	<b>9,746</b>
Amortisation expense	-	1,089	740	57	1,886
<b>At 31 December 2025</b>	-	<b>5,652</b>	<b>5,708</b>	<b>272</b>	<b>11,632</b>
<b>Carrying value</b>					
<b>At 30 June 2025</b>	<b>67,763</b>	<b>11,032</b>	<b>11,431</b>	<b>126</b>	<b>90,352</b>
<b>At 31 December 2025</b>	<b>67,763</b>	<b>9,943</b>	<b>10,691</b>	<b>69</b>	<b>88,466</b>

## 7. Issued capital

Consolidated	6 Months to 31 December 2025		12 months to 30 June 2025	
	No.	\$000	No.	\$000
Opening balance	1,342,952,696	115,515	1,342,473,221	115,511
Shares issued during the period:				
Performance rights vested	-	-	479,475	-
<b>Closing balance</b>	<b>1,342,952,696</b>	<b>115,515</b>	<b>1,342,952,696</b>	<b>115,515</b>

Fully paid ordinary shares carry one vote per share and carry the right to dividends.

## 8. Dividends

There were no dividends paid or proposed during the period. (Prior year: nil)

## 9. Earnings/(loss) per share

Earnings/(loss) per share	31 Dec 2025 Cents	31 Dec 2024 Cents
Basic and diluted earnings/(loss) per share	0.10	(0.07)

### (a) Earnings used in calculating basic and diluted earnings per share

	31 Dec 2025 \$000	31 Dec 2024 \$000
Profit/(loss) attributable to ordinary shareholders of the Group used in calculating basic and diluted earnings/(loss) per share	1,330	(889)

### (b) Weighted average number of shares used as denominator to calculate basic and diluted earnings per share

	December 2025 No.	December 2024 No.
Weighted average number of ordinary shares used in calculating basic & diluted earnings per share	1,342,952,696	1,342,744,229

## 10. Commitments

As at 31 December 2025 the Group has no commitments (30 June 2025: nil)

## 11. Contingencies

In the opinion of the Directors, the Group did not have any contingent liabilities or contingent assets as at 31 December 2025 (30 June 2025: nil).

## 12. Segment reporting

The Group operates in the healthcare industry in Australia, New Zealand and the UK. For management purposes, the Group is organised into one main operating segment which involves the provision of healthcare software solutions in all these territories. All the Group's activities are inter-related and financial information is reported to the Board (Chief Operating Decision Maker) as a single segment. All significant operating decisions are based upon analysis of the Group as one segment. The financial results of this segment are therefore equivalent to the financial statements of the Group.

### Basis of accounting for purposes of reporting by operating segments

#### Accounting policies adopted

Unless stated otherwise, all amounts reported to the Board of Directors, being the chief operating decision makers with respect to operating segments, are determined in accordance with accounting policies that are consistent with those adopted in the annual financial statements of the Group.

#### Intersegment transactions

There were no intersegment sales during the period.

#### Segment information

Group Performance - No separate Group performance has been presented in this report as the Board receives only a consolidated Group performance report which is the equivalent to the statement of Profit or Loss and Other Comprehensive Income of the Group as a whole.

Group assets and liabilities - No separate Group asset and liabilities have been presented in this report as the Board only receives a consolidated asset and liabilities report which is the equivalent to the statement of financial position of the Group as a whole.

Revenue by geographical region	31 Dec 2025		31 Dec 2024	
	\$000	%	\$000	%
Australia / New Zealand	12,177	48%	10,096	57%
United Kingdom	13,293	52%	7,542	43%
<b>Total revenue</b>	<b>25,470</b>		<b>17,638</b>	

Timing of revenue recognition	31 Dec 2025 \$000			31 Dec 2024 \$000		
	Goods transferred at a point in time	Service transferred over time	Total	Goods transferred at a point in time	Service transferred over time	Total
Australia / New Zealand	9,389	2,788	12,177	6,467	3,629	10,096
United Kingdom	10,883	2,410	13,293	7,222	320	7,542
<b>Total revenue</b>	<b>20,272</b>	<b>5,198</b>	<b>25,470</b>	<b>13,689</b>	<b>3,949</b>	<b>17,638</b>

#### Major customers

During the period the group had two customers that individually accounts for more than 10% of revenue:

- Leidos Australia \$6,647K (26.1%) (Dec 24: \$4,627K (26.2%))
- North Cumbria Integrated Care NHS Foundation Trust \$3,224k (12.7%) (Dec 24: \$293K (1.7%))

### 13. Related party disclosures

(a) **Loans to key management personnel and their related parties**

There have been no loans to key management personnel during the current or previous financial year.

(b) **Other transactions with key management personnel**

For the period 1 July 2025 to 31 December 2025 there were no related party transactions to report.

Balance payable to related parties as at 31 December 2025 was \$Nil (30 June 2025: \$Nil).

Transactions between related parties are on normal commercial terms and conditions no more or less favourable than those available to other parties.

### 14. Events after the end of the interim period

Subsequent to the period end Alcidion announced that it has been selected as the preferred EPR supplier by University Hospitals Sussex NHS Foundation Trust (UHSussex) for its new Electronic Patient Record (EPR) system. UHSussex is located in the south of the UK and forms part of the Sussex Integrated Care System (ICS). They provide hospital and community health care for approximately a million people in Sussex. It is one of the largest acute trusts in the UK, with seven hospitals hosting more than 1.5 million outpatient appointments, A&E visits and surgery cases annually, employing nearly 20,000 staff.

Alcidion will deploy their flagship Miya Precision platform, including Miya Observations and Assessments (Patientrack), which is already live at the Trust. The EPR solution will provide clinicians real-time access to patient records whilst streamlining patient flow and improving clinical decision-making processes.

Other than the events detailed above no matter or circumstances have arisen since the end of the half-year reporting period which significantly affect the operations of the Group, the results of those operations or the state of affairs of the Group in future years.

## Directors' declaration

The directors declare that:

- a) in the directors' opinion, there are reasonable grounds to believe that the Company will be able to pay its debts as and when they become due and payable; and
- b) in the directors' opinion, the attached financial statements and notes thereto are in accordance with the *Corporations Act 2001*, including compliance with accounting standards and giving a true and fair view of the financial position and performance of the Group for the half year ended 31 December 2025.

Signed in accordance with a resolution of the directors made pursuant to s.303(5) of the *Corporations Act 2001*.

On behalf of the Directors



**Rebecca Wilson**  
Non-Executive Chair  
Melbourne, 26 February 2026

For personal use only

**Independent Auditor's Review Report****Independent auditor's review report to the members of Alcidion Group Limited****Report on the half-year financial report****Our conclusion**

Based on our review, which is not an audit, we have not become aware of any matter that makes us believe that the accompanying half-year financial report of Alcidion Group Limited (the Company), and its subsidiaries (the Group) does not comply with the *Corporations Act 2001*, including:

- giving a true and fair view of the Group's financial position as at 31 December 2025 and of its financial performance for the half-year then ended; and
- complying with Accounting Standard AASB 134 *Interim Financial Reporting* and the *Corporations Regulations 2001*.

**What was reviewed?**

We have reviewed the accompanying half-year financial report of the Group, which comprises:

- the consolidated statement of financial position as at 31 December 2025,
- the consolidated statement of profit or loss and other comprehensive income for the half-year then ended,
- the consolidated statement of changes in equity for the half-year then ended,
- the consolidated statement of cash flows for the half-year then ended,
- notes to the financial statements, including material accounting policy information, and
- the directors' declaration.

**Basis for conclusion**

We conducted our review in accordance with ASRE 2410 *Review of a Financial Report Performed by the Independent Auditor of the Entity*. Our responsibilities are further described in the *Auditor's responsibilities for the review of the financial report* section of our report. We are independent of the Group in accordance with the auditor independence requirements of the *Corporations Act 2001* and the ethical requirements of the Accounting Professional and Ethical Standards Board's APES 110 *Code of Ethics for Professional Accountants (including Independence Standards)* (the Code) that are relevant to our audit of the annual financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

## Independent Auditor's Review Report

### Responsibilities of the directors for the financial report

The directors of the Company are responsible for the preparation of the half-year financial report that gives a true and fair view in accordance with Australian Accounting Standards and the *Corporations Act 2001* and for such internal control as the directors determine is necessary to enable the preparation of the half-year financial report that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

### Auditor's responsibilities for the review of the financial report

Our responsibility is to express a conclusion on the half-year financial report based on our review. ASRE 2410 requires us to conclude whether we have become aware of any matter that makes us believe that the half-year financial report is not in accordance with the *Corporations Act 2001* including giving a true and fair view of the Group's financial position as at 31 December 2025 and its performance for the half-year ended on that date, and complying with Accounting Standard AASB 134 *Interim Financial Reporting* and the *Corporations Regulations 2001*.

A review of a half-year financial report consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Australian Auditing Standards and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



**William Buck (SA)**  
ABN: 38 280 203 274



**G.W. Martinella**  
Partner

Dated this 26<sup>th</sup> day of February, 2026.

## Corporate Directory

### Current Directors (Alcidion Group Limited)

Name	Position	Date of Appointment
Ms Rebecca Wilson	Non-Executive Chair	01/08/2017
Ms Kate Quirke	Managing Director	03/07/2018
Mr Daniel Sharp	Non-Executive Director	01/09/2021
Mr William Smart	Non-Executive Director	01/10/2024
Prof. Andrew Way AM	Non-Executive Director	15/04/2025
Mr Michael Sapountzis	Company Secretary	25/10/2024

#### Registered office

Suite 2, Level 11  
385 Bourke Street  
Melbourne VIC 3000

#### Principal place of business

Level 10  
9 Yarra Street  
South Yarra VIC 3141  
☎ 1800 767 873

#### Website

[www.alcidion.com](http://www.alcidion.com)

#### Registers of securities

Computershare Investor Services Pty Ltd  
Level 5, 115 Grenfell Street,  
Adelaide SA 5000

#### Auditors

William Buck  
Level 6, 211 Victoria Square  
Adelaide SA 5000

☎ +61 8 8409 4333

☎ +61 8 8409 4499

#### J.S. Audit Limited

James House, Stonecross Business Park  
Yew Tree Way, Warrington  
Cheshire, WA3 3JD

☎ +44 1942 292500

#### Stock Exchange

Australian Securities Exchange Limited  
Exchange Centre  
20 Bridge Street  
Sydney, NSW 2000

ASX Code: **ALC**

#### Tax Accountants

BDO  
Level 11, 1 Margaret St  
Sydney, NSW, 2000

☎ +61 2 9251 4100

#### Bankers

Westpac Banking Corporation  
Level 30, 275 Kent Street  
Sydney, NSW, 2000

☎ 1300 134 291



**ALCIDION**



## **ABOUT ALCIDION**

Alcidion Group Limited (Alcidion) has a simple purpose, that is, to transform healthcare with proactive, smart, intuitive technology solutions that improve the efficiency and quality of patient care in healthcare organisations, worldwide.

Alcidion offers a complementary set of software products and technical services that create a unique offering in the global healthcare market. Based on the flagship product, Miya Precision, the solutions aggregate meaningful information to centralised dashboards, support interoperability, facilitate communication and task management in clinical and operational settings and deliver Clinical Decision Support at the point of care; all in support of Alcidion's mission to improve patient outcomes.

Since listing on the ASX in 2011, Alcidion has acquired multiple healthcare IT companies and expanded its foothold in the UK, Australia, and New Zealand to now service over 400 hospitals and 87 healthcare organisations, with further geographical expansion planned.

With over 20 years of healthcare experience, Alcidion brings together the very best in technology and market knowledge to deliver solutions that make healthcare better for everyone.

© Alcidion Group Limited 2026. Alcidion, Miya Precision, Patientrack and Smartpage are registered trademarks. All other brands and product names and trademarks are the registered property of their respective companies.

[www.alcidion.com](http://www.alcidion.com)  
[investor@alcidion.com](mailto:investor@alcidion.com)

### **Head Office**

Level 10, 9 Yarra Street  
SOUTH YARRA VIC 3141  
AUSTRALIA  
P 1800 767 873